End-to-end
agentic discovery for
first-in-class drugs
Every phase of drug discovery has dozens of bottlenecks, so fixing them one at a time doesn't fundamentally change its pace. That's why we put agents in the driver's seat across the whole arc. Our agents make the day-to-day decisions and know when to escalate to a scientist.
With our platform, Allchymie, we now run the entire hit ID phase in 12 weeks, at a seventh of the industry cost.
Investors
Partners
Our Team
We assembled a team that can build drugs and agents together
Hannah Shen, PhD
Founder & CEO
- Early employee across biotech (BridgeBio) and techbio (Benchling, Octant).
- Builds platform modules for strategy, operations, and biology.
Ching-Yi Lin
Founding Head of Engineering
- Founding engineer for 3 products at Salesforce/MuleSoft spanning AI, automation, and cloud orchestration.
- Builds platform engineering modules and productionizes Allchymie.
Chaya Stern, PhD
Founding Head of Computational Chemistry
- Built physics+AI/ML and drug program platforms at DeepCure and Odyssey.
- Builds platform modules for drug design and AI/ML predictions.
Heidi Koldsø, PhD
Head of Computational Drug Design
- Advanced programs from hit to DC including first-in-class and undruggable targets at Antares/Scorpion.
- Leads Kekulai's drug programs to train and validate the platform.
Claudia Cremers, PhD
Founding Head of Discovery
- Led small-molecule discovery against transcription factors at Flare.
- Leads Kekulai's assay development and execution.
Ching-Wen Hsu
Senior Engineer
- Integrated ~1,700 disparate AI models into one system any team could use at Facebook.
- Productionizes Kekulai's agents.
Contact us
hello@kekulai.com
